Teh Seng Pharmaceutical Mfg Co Ltd
TTPEX:786076.70
TWD
0.00
(0.00%)
ISIN
TW0007860009
Return %
Stock
S&P 500
1Y
-5.31
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Hai Shang Hsu
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Tainan Taiwan
- Website
- tehseng.com
- Similar Companies
- Business
- Teh Seng Pharmaceutical Mfg. Co., Ltd. is a Taiwan-based pharmaceutical manufacturing company specializing in transdermal drug delivery systems (TDDS), topical therapeutic formulations, and herbal healthcare products. Founded in 1975 and headquartered in Tainan City, Taiwan, the company operates across prescription pharmaceuticals, over-the-counter (OTC) consumer health, traditional Chinese medicine, and contract development and manufacturing organization (CDMO/OEM/ODM) business segments. The company's core product portfolio comprises hydrogel cataplasms and transdermal pain relief patches; anti-inflammatory and analgesic medicated plasters formulated with active ingredients such as diclofenac, indomethacin, capsicum extract, and methyl salicylate; traditional herbal plaster preparations and botanical extracts; topical ointments, creams, sprays, and gels for dermatological and musculoskeletal applications; medical wound dressings and fever cooling sheets; and dietary health supplements. Teh Seng distributes its products to medical centers, clinics, retail pharmacy chains, and multinational pharmaceutical enterprises across Taiwan, North America, Japan, Europe, Southeast Asia, and Greater China. In recent developments, Teh Seng registered on the Taipei Exchange Emerging Stock Board under ticker 7860 to broaden its institutional investor base and finance strategic growth initiatives. The company has expanded its PIC/S GMP-certified manufacturing infrastructure with automated high-speed coating and packaging lines to increase production capacity for advanced TDDS patches. In addition, Teh Seng has deepened its strategic CDMO alliances with international pharmaceutical partners to co-develop next-generation controlled-release hydrogel formulations for pain management and topical therapies.